Plasma protein binding in drug discovery and development
- PMID: 20053162
- DOI: 10.2174/138620710790596745
Plasma protein binding in drug discovery and development
Abstract
This review describes methods for quantifying the binding of small molecule drug candidates to plasma proteins and the application of these methods in drug discovery and development. Particular attention is devoted to methods amenable to medium-to-high throughput analysis and those well suited for measurement of compounds that are highly protein bound. The methods reviewed herein include the conventional techniques of equilibrium dialysis, ultrafiltration and ultracentrifugation, as well as some more novel approaches utilizing micropartitioning and biosensor-based analysis. Additional concepts that are discussed include plasma protein structure, enantioselective protein binding, drug displacement, the effect of patient demographics and disease states on free (unbound) drug levels, and the influence of protein binding on drug candidate pharmacokinetics and pharmacodynamics. Practical considerations pertaining to the evaluation of highly protein bound drug candidates are also highlighted.
Similar articles
-
Global analytical strategy to measure drug-plasma protein interactions: from high-throughput to in-depth analysis.Drug Discov Today. 2013 Nov;18(21-22):1030-4. doi: 10.1016/j.drudis.2013.04.006. Epub 2013 Apr 18. Drug Discov Today. 2013. PMID: 23603634
-
Do we need to optimize plasma protein and tissue binding in drug discovery?Curr Top Med Chem. 2011;11(4):450-66. doi: 10.2174/156802611794480918. Curr Top Med Chem. 2011. PMID: 21320069 Review.
-
Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences.Clin Pharmacokinet. 1992 Dec;23(6):449-68. doi: 10.2165/00003088-199223060-00005. Clin Pharmacokinet. 1992. PMID: 1458763 Review.
-
High performance affinity chromatography (HPAC) as a high-throughput screening tool in drug discovery to study drug-plasma protein interactions.J Pharm Biomed Anal. 2013 Feb 23;74:205-12. doi: 10.1016/j.jpba.2012.10.030. Epub 2012 Nov 5. J Pharm Biomed Anal. 2013. PMID: 23245252
-
Development and validation of a higher-throughput equilibrium dialysis assay for plasma protein binding.J Lab Autom. 2011 Feb;16(1):56-67. doi: 10.1016/j.jala.2010.06.002. Epub 2011 Jan 12. J Lab Autom. 2011. PMID: 21609686
Cited by
-
In vivo studies of a peptidomimetic that targets EGFR dimerization in NSCLC.J Cancer. 2020 Aug 18;11(20):5982-5999. doi: 10.7150/jca.46320. eCollection 2020. J Cancer. 2020. PMID: 32922539 Free PMC article.
-
Irreversible binding of an anticancer compound (BI-94) to plasma proteins.Xenobiotica. 2015;45(10):858-73. doi: 10.3109/00498254.2015.1025250. Epub 2015 Apr 14. Xenobiotica. 2015. PMID: 25869245 Free PMC article.
-
A structure-based model for predicting serum albumin binding.PLoS One. 2014 Apr 1;9(4):e93323. doi: 10.1371/journal.pone.0093323. eCollection 2014. PLoS One. 2014. PMID: 24691448 Free PMC article.
-
Considerations in Kp,uu,brain-based Strategy for Selecting CNS-targeted Drug Candidates with Sufficient Target Coverage and Substantial Pharmacodynamic Effect.AAPS J. 2025 Feb 28;27(2):52. doi: 10.1208/s12248-025-01035-8. AAPS J. 2025. PMID: 40021548
-
Investigation of Minipigs as the Optimal Non-rodent Pre-clinical Species: Exploring Plasma Protein Binding of Marketed Cardiovascular Drugs Across Species.AAPS PharmSciTech. 2024 Dec 5;26(1):4. doi: 10.1208/s12249-024-03005-3. AAPS PharmSciTech. 2024. PMID: 39638965
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical